Developer docs
API playgroundTry for free, no card

Search company profiles

Immune Tolerance Network

Full company profile

uuid000suet

Namestring
Immune Tolerance Network
Legal namestring
Immune Tolerance Network
Company typeenum
Private
Founded yearstring
-
Descriptiontext

The Immune Tolerance Network (ITN) is a federally sponsored clinical research consortium that develops, funds, and conducts mechanistic clinical trials aimed at re-establishing immune tolerance across four therapeutic areas: allergy and asthma, autoimmune disease, transplantation, and type 1 diabetes. ITN's core technical assets include the TrialShare data platform, which provides public access to raw clinical trial data, analyses, and banked specimens (including plasma from 582+ LEAP trial participants), and a suite of standardized immune monitoring assays measuring islet-specific T cell responses, immune phenotypes, and tolerance biomarkers. The network's trial portfolio encompasses ongoing studies such as EVEREST (liver transplant tolerance), REBOOT (Primary Membranous Nephropathy), BEAT-MS (multiple sclerosis), VIBRANT (lupus nephritis), DESIGNATE (siplizumab in T1D), and EXTEND (tocilizumab in T1D), conducted across leading academic medical centers including UCSF, Benaroya Research Institute, Northwestern, Yale, and Indiana University.

ITN operates as a non-profit research consortium under the sponsorship of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, with offices at the Benaroya Research Institute in Seattle and at UCSF in San Francisco. The organization does not charge patients for trial participation and generates no commercial product revenue; its operating model relies on federal appropriations channeled through NIAID, supplemented by collaborative partnerships with patient advocacy organizations (JDRF, Diabetes UK) and trial consortia (TrialNet). The organization is led by Network Director Mark Anderson MD PhD (UCSF), Deputy Director for Transplantation Chris Larsen, Senior Advisor Gerald Nepom, Chief Administrative Officer Mary Roy, Executive Director of Strategic Review Philip Bernstein, and Clinical Trial Physician for Allergy Michelle Huffaker. Notable scientific outcomes include ITN's foundational AbATE trial work that supported the 2026 FDA approval of teplizumab (Tzield) as the first disease-modifying therapy for stage 3 type 1 diabetes, and the LEAP/LEAP-On studies that established early peanut consumption as a strategy to reduce peanut allergy risk in infants.

Short descriptiontext

The Immune Tolerance Network (ITN) is a federally funded research consortium sponsored by NIAID/NIH that develops and conducts mechanistic clinical trials across allergy, autoimmune disease, transplantation, and type 1 diabetes to advance immune tolerance therapies.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial research, immune tolerance therapies, transplant immunology, autoimmune disease research, type 1 diabetes research
Industry1 code
PRIMARYHLAAALAK
Autoimmune & Allergy Diagnostics
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
Product category
Clinical Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Government Research Funding
TypeSubscription Recurring
Description

ITN is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, providing primary funding for clinical trials and research operations

immunetolerance.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ITN is a research consortium that develops, funds, and conducts mechanistic clinical trials designed to re-establish immune tolerance in four therapeutic areas: allergy & asthma, autoimmune disease, transplantation, and type 1 diabetes. It operates TrialShare, a web-based data sharing platform providing researchers with access to raw clinical trial data, analysis tools, and banked clinical specimens from over 15 years of trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Teplizumab (anti-CD3) approved by FDA as first disease-modifying therapy for Stage 3 T1D
+2 more records
Product overview1 text field

The Immune Tolerance Network (ITN) is a research consortium that develops, funds, and conducts clinical trials in immune tolerance. The organization operates TrialShare as its primary data platform providing access to raw clinical trial data, analyses, and specimens. ITN's clinical trial portfolio spans four therapeutic areas: Allergy & Asthma, Autoimmune Disease, Transplantation, and Type 1 Diabetes. The network conducts mechanistic-based clinical studies designed to test specific immune tolerance pathways and partners with industry and other consortia to accelerate development of tolerance-inducing therapies.

Product and service1 record
1TrialShare
CategoryData Sharing Platform
Description

A web-based data sharing platform that provides researchers with access to raw data, analysis tools, and clinical specimens from ITN's clinical trials in immune tolerance across four therapeutic areas.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ITN partners with JDRF on type 1 diabetes research, including establishing a multi-center network for preclinical screening of combination therapies to accelerate translation to clinic

2Diabetes UK
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative partner for type 1 diabetes mechanistic assay development and standardization through TrialShare

immunetolerance.org
3TrialNet
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaborative consortium partner for sharing T1D mechanistic assays and harmonizing data analysis across trials

immunetolerance.org
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical trial site for liver transplant tolerance study (EVR and EPO), led by Dr. Sandy Feng

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Primary research partner and office location; hosts Network Director Mark Anderson; multiple trial sites including liver transplant and T1D studies

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Seattle-based office location; hosts T1D trials including EXTEND tocilizumab study under Drs. Greenbaum and Buckner

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Clinical trial site for AbATE teplizumab study under Dr. Kevan Herold

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Sanofi acquired Provention Bio, the developer of teplizumab (Tzield)—the asset originated in ITN's AbATE trial. As the commercializer of ITN-validated therapies, Sanofi is the principal downstream industry partner benefiting from ITN's pipeline.

2AIDS Clinical Trials Group (ACTG)
TypeDirect peer
Description

NIAID-sponsored clinical trials network running multicenter trials in HIV therapeutics. Operates under the same NIAID/NIH funding model as ITN and uses comparable multicenter academic medical center trial infrastructure with centralized specimen and data sharing.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company developing antibody-based therapeutics in immune tolerance and oncology. Pursues overlapping T cell and immune pathway targets, though as a commercial biotech rather than a research consortium.

4Abata Therapeutics
TypeEmerging player
Description

Biotech developing engineered regulatory T cell (Treg) therapies for autoimmune disease. Conceptually aligned with ITN's Treg-enhancement mechanistic trial designs and pursues overlapping indications in autoimmunity.

TypeDirect peer
Description

NCI-funded pediatric cancer clinical trials consortium with a longstanding multicenter academic model, standardized protocols, and shared specimen/data assets. Operationally comparable to ITN's structure across four therapeutic disease areas.

TypeEmerging player
Description

Clinical-stage biotech developing tolerogenic immunotherapies and cell therapy platforms designed to modulate immune response. Operates in the same immune tolerance therapeutic space as ITN-funded academic trials.

7National Institute of Allergy and Infectious Diseases (NIAID)
TypeOthers
Description

ITN's primary federal sponsor and an enabling organization that funds the network's clinical trial operations. Not a competing peer but the institution whose priorities directly shape ITN's research agenda and funding continuity.

TypeDirect peer
Description

CITN conducts early-phase immunotherapy clinical trials through a network of leading academic centers, sharing ITN's structure of mechanistic trial design, biomarker/immune monitoring, and partnership with NIH-funded institutions.

9Type 1 Diabetes TrialNet
TypeDirect peer
Description

NIH-funded clinical trial network focused on Type 1 Diabetes prevention and intervention. ITN's designated partner in T1D research and the closest structural sibling—same NIH sponsorship model, same multi-center academic trial design, overlapping principal investigators.

10NIAID Inner-City Asthma Consortium (ICAC)
TypeDirect peer
Description

NIAID-funded clinical trial network conducting allergen and asthma intervention trials in pediatric populations. Directly comparable to ITN's allergy and asthma therapeutic area and shares the same NIAID sponsorship.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immune Tolerance Network

Clinical Research Servicesimmunetolerance.org

The Immune Tolerance Network (ITN) is a federally funded research consortium sponsored by NIAID/NIH that develops and conducts mechanistic clinical trials across allergy, autoimmune disease, transplantation, and type 1 diabetes to advance immune tolerance therapies.

What Immune Tolerance Network does

The Immune Tolerance Network (ITN) is a federally sponsored clinical research consortium that develops, funds, and conducts mechanistic clinical trials aimed at re-establishing immune tolerance across four therapeutic areas: allergy and asthma, autoimmune disease, transplantation, and type 1 diabetes. ITN's core technical assets include the TrialShare data platform, which provides public access to raw clinical trial data, analyses, and banked specimens (including plasma from 582+ LEAP trial participants), and a suite of standardized immune monitoring assays measuring islet-specific T cell responses, immune phenotypes, and tolerance biomarkers. The network's trial portfolio encompasses ongoing studies such as EVEREST (liver transplant tolerance), REBOOT (Primary Membranous Nephropathy), BEAT-MS (multiple sclerosis), VIBRANT (lupus nephritis), DESIGNATE (siplizumab in T1D), and EXTEND (tocilizumab in T1D), conducted across leading academic medical centers including UCSF, Benaroya Research Institute, Northwestern, Yale, and Indiana University.

ITN operates as a non-profit research consortium under the sponsorship of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, with offices at the Benaroya Research Institute in Seattle and at UCSF in San Francisco. The organization does not charge patients for trial participation and generates no commercial product revenue; its operating model relies on federal appropriations channeled through NIAID, supplemented by collaborative partnerships with patient advocacy organizations (JDRF, Diabetes UK) and trial consortia (TrialNet). The organization is led by Network Director Mark Anderson MD PhD (UCSF), Deputy Director for Transplantation Chris Larsen, Senior Advisor Gerald Nepom, Chief Administrative Officer Mary Roy, Executive Director of Strategic Review Philip Bernstein, and Clinical Trial Physician for Allergy Michelle Huffaker. Notable scientific outcomes include ITN's foundational AbATE trial work that supported the 2026 FDA approval of teplizumab (Tzield) as the first disease-modifying therapy for stage 3 type 1 diabetes, and the LEAP/LEAP-On studies that established early peanut consumption as a strategy to reduce peanut allergy risk in infants.

Immune Tolerance Network firmographics

Firmographics
Name
Immune Tolerance Network
Legal name
Immune Tolerance Network
Website
https://immunetolerance.org
Company type
Private
Operating status
Operating
Headcount range
11–50 employees
Short description
The Immune Tolerance Network (ITN) is a federally funded research consortium sponsored by NIAID/NIH that develops and conducts mechanistic clinical trials across allergy, autoimmune disease, transplantation, and type 1 diabetes to advance immune tolerance therapies.
Ownership category
akta.pro rank

Immune Tolerance Network industry classification

Industry
Product category
Clinical Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAAALAK
Autoimmune & Allergy Diagnostics

Keywords

  • Clinical trial research
  • Immune tolerance therapies
  • Transplant immunology
  • Autoimmune disease research
  • Type 1 diabetes research

Where Immune Tolerance Network is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Immune Tolerance Network business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. Government Research Funding: ITN is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, providing primary funding for clinical trials and research operations

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Immune Tolerance Network product offering

Product offering

Core offering

ITN is a research consortium that develops, funds, and conducts mechanistic clinical trials designed to re-establish immune tolerance in four therapeutic areas: allergy & asthma, autoimmune disease, transplantation, and type 1 diabetes. It operates TrialShare, a web-based data sharing platform providing researchers with access to raw clinical trial data, analysis tools, and banked clinical specimens from over 15 years of trials.

Product overview

The Immune Tolerance Network (ITN) is a research consortium that develops, funds, and conducts clinical trials in immune tolerance. The organization operates TrialShare as its primary data platform providing access to raw clinical trial data, analyses, and specimens. ITN's clinical trial portfolio spans four therapeutic areas: Allergy & Asthma, Autoimmune Disease, Transplantation, and Type 1 Diabetes. The network conducts mechanistic-based clinical studies designed to test specific immune tolerance pathways and partners with industry and other consortia to accelerate development of tolerance-inducing therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • TrialShare A web-based data sharing platform that provides researchers with access to raw data, analysis tools, and clinical specimens from ITN's clinical trials in immune tolerance across four therapeutic areas.

Quantifiable outcome

  • Teplizumab (anti-CD3) approved by FDA as first disease-modifying therapy for Stage 3 T1D
  • +2 more outcomes

Companies that use Immune Tolerance Network

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Immune Tolerance Network technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Immune Tolerance Network partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • JDRF (Juvenile Diabetes Research Foundation)coreStrategic or Co-development PartnerITN partners with JDRF on type 1 diabetes research, including establishing a multi-center network for preclinical screening of combination therapies to accelerate translation to clinic
  • Diabetes UKminorStrategic or Co-development PartnerCollaborative partner for type 1 diabetes mechanistic assay development and standardization through TrialShare
  • TrialNetminorStrategic or Co-development PartnerCollaborative consortium partner for sharing T1D mechanistic assays and harmonizing data analysis across trials
  • Northwestern UniversityminorImplementation/ SI/ Consulting PartnerClinical trial site for liver transplant tolerance study (EVR and EPO), led by Dr. Sandy Feng
  • UCSF (University of California San Francisco)coreImplementation/ SI/ Consulting PartnerPrimary research partner and office location; hosts Network Director Mark Anderson; multiple trial sites including liver transplant and T1D studies
  • Benaroya Research InstitutecoreImplementation/ SI/ Consulting PartnerSeattle-based office location; hosts T1D trials including EXTEND tocilizumab study under Drs. Greenbaum and Buckner
  • Yale School of MedicineminorImplementation/ SI/ Consulting PartnerClinical trial site for AbATE teplizumab study under Dr. Kevan Herold

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Immune Tolerance Network competitors and assessment

Company assessment

Broad incumbents

  • Provention Bio (a Sanofi company): Sanofi acquired Provention Bio, the developer of teplizumab (Tzield)—the asset originated in ITN's AbATE trial. As the commercializer of ITN-validated therapies, Sanofi is the principal downstream industry partner benefiting from ITN's pipeline.

Direct peers

  • AIDS Clinical Trials Group (ACTG): NIAID-sponsored clinical trials network running multicenter trials in HIV therapeutics. Operates under the same NIAID/NIH funding model as ITN and uses comparable multicenter academic medical center trial infrastructure with centralized specimen and data sharing.
  • Children's Oncology Group (COG): NCI-funded pediatric cancer clinical trials consortium with a longstanding multicenter academic model, standardized protocols, and shared specimen/data assets. Operationally comparable to ITN's structure across four therapeutic disease areas.
  • Cancer Immunotherapy Trials Network (CITN): CITN conducts early-phase immunotherapy clinical trials through a network of leading academic centers, sharing ITN's structure of mechanistic trial design, biomarker/immune monitoring, and partnership with NIH-funded institutions.
  • Type 1 Diabetes TrialNet: NIH-funded clinical trial network focused on Type 1 Diabetes prevention and intervention. ITN's designated partner in T1D research and the closest structural sibling—same NIH sponsorship model, same multi-center academic trial design, overlapping principal investigators.
  • NIAID Inner-City Asthma Consortium (ICAC): NIAID-funded clinical trial network conducting allergen and asthma intervention trials in pediatric populations. Directly comparable to ITN's allergy and asthma therapeutic area and shares the same NIAID sponsorship.

Emerging players

  • MacroGenics: Clinical-stage biopharmaceutical company developing antibody-based therapeutics in immune tolerance and oncology. Pursues overlapping T cell and immune pathway targets, though as a commercial biotech rather than a research consortium.
  • Abata Therapeutics: Biotech developing engineered regulatory T cell (Treg) therapies for autoimmune disease. Conceptually aligned with ITN's Treg-enhancement mechanistic trial designs and pursues overlapping indications in autoimmunity.
  • Cartesian Therapeutics (formerly Selecta Biosciences): Clinical-stage biotech developing tolerogenic immunotherapies and cell therapy platforms designed to modulate immune response. Operates in the same immune tolerance therapeutic space as ITN-funded academic trials.

Others

  • National Institute of Allergy and Infectious Diseases (NIAID): ITN's primary federal sponsor and an enabling organization that funds the network's clinical trial operations. Not a competing peer but the institution whose priorities directly shape ITN's research agenda and funding continuity.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Immune Tolerance Network social profiles

Digital presence

Immune Tolerance Network compliance and trust

Trust signal

Compliance1 record

Immune Tolerance Network financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immune Tolerance Network leadership team

Management profile

Number of profiles

Profiles6 records

Immune Tolerance Network funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immune Tolerance Network M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immune Tolerance Network

What does Immune Tolerance Network do?

ITN is a research consortium that develops, funds, and conducts mechanistic clinical trials designed to re-establish immune tolerance in four therapeutic areas: allergy & asthma, autoimmune disease, transplantation, and type 1 diabetes. It operates TrialShare, a web-based data sharing platform providing researchers with access to raw clinical trial data, analysis tools, and banked clinical specimens from over 15 years of trials.

Is Immune Tolerance Network a public or private company?

Immune Tolerance Network is a private company. It is classified as state government owned and is currently operating.

When was Immune Tolerance Network founded?

Immune Tolerance Network was founded in -1. It employs 11 to 50 people.

Where is Immune Tolerance Network based?

Immune Tolerance Network is headquartered in Seattle, United States, in the North America region.

How does Immune Tolerance Network make money?

One revenue line is on record: government Research Funding.

Who are Immune Tolerance Network's main competitors?

Provention Bio (a Sanofi company) is listed as a broad incumbent. Direct peers are AIDS Clinical Trials Group (ACTG), Children's Oncology Group (COG), Cancer Immunotherapy Trials Network (CITN), Type 1 Diabetes TrialNet and NIAID Inner-City Asthma Consortium (ICAC). Emerging players are MacroGenics, Abata Therapeutics and Cartesian Therapeutics (formerly Selecta Biosciences). National Institute of Allergy and Infectious Diseases (NIAID) is listed as an others.

Does Immune Tolerance Network have an API?

No public API is recorded for Immune Tolerance Network.

What industry is Immune Tolerance Network in?

Immune Tolerance Network's product category is Clinical Research Services. Its primary akta.pro industry code is HLAAALAK, Autoimmune & Allergy Diagnostics. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals